Monographie - Colistin mesilate sodium

最新更新 :
19/11/2024

Colistin mesilate sodium

化学式

商品名

商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。

Alfacolin	阿根廷
Alficetin	阿根廷
Colent	智利
Colimicina	意大利, 西班牙
Colimycin	丹麦, 土耳其, 挪威
Colimycine	卢森堡, 摩洛哥, 法国, 突尼斯, 荷兰
Colismet	秘鲁
Colisti Ject	埃及
Colistimetal sodic	罗马尼亚
Colistimetato de sodio	智利, 秘鲁, 西班牙
Colistimethate	加拿大, 美国, 英国
Colistin	奥地利, 希腊, 新西蘭, 波兰
Colistina	葡萄牙, 阿根廷
Colistineb	比利时
Colistyn	阿根廷
Colixin	葡萄牙
Colomycin	加拿大, 爱尔兰, 美国, 英国, 马来西亚
Coly-Mycin	澳大利亚, 美国
Cotrelan	阿根廷
Dicupal	智利
Elistin	秘鲁
Kolisod	土耳其
Nolisin	阿根廷
Promixin	挪威, 爱尔兰, 英国
Toliscrin	阿根廷

引用文献 : Colistin mesilate sodium

	种类	出版物
1201	文献	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
2285	文献	Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008 ; 52, 9: 3047-3051.
2550	文献	Roberts GW, Rossi S.O.P. Compatibility of nebulizer solutions Aust J Hosp Pharm 1993 ; 23: 35-37.
2783	文献	Abdulla A,.van Leeuwen R.W.F, de Vries Schultink A.H.M,.Koch B.C.P. Stability of colistimethate sodium in a disposable elastomeric infusion device. Int J Pharm 2015 ; 486; 1-2: 367-369.
3254	文献	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3360	文献	Healan A. M, Gray W, Fuchs E.J, Griffiss J.M, Salata R.A, Blumer J. Stability of Colistimethate Sodium in Aqueous Solution. Antimicrob Agents Chemother 2012 ; 56:6432-6433.
3674	实验室	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	海报	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	海报	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	海报	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3997	文献	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	文献	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	文献	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4178	文献	Post T.E, Kamerling I, van Rossen R, Burggraaf J, Stevens J, Dijkmans A, Heijerman H, Touw D, van Velzen A, Wilms E. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. EJHP 2017 ; 25, e2
4319	文献	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4434	文献	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4438	文献	Stawny M, Gostyńska A, Nadolna M, Jelińska A. Safe Practice of Y-Site Drug Administration: The Case of Colistin and Parenteral Nutrition Pharmaceutics 2020 ; 12: 292
4528	文献	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	文献	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales